<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>WHO Classification of tumors of the vulva*&lt;sup&gt;¶&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">WHO Classification of tumors of the vulva*<sup>¶</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">WHO Classification of tumors of the vulva*<sup>¶</sup></div><div class="cntnt"><table cellspacing="0" class="container"><colgroup span="2" width="50%"></colgroup> <tbody> <tr> <td class="container"> <table cellspacing="0"> <colgroup width="80%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1_single" colspan="2">Epithelial tumors</td> </tr> <tr> <td class="subtitle2_single">Squamous cell tumors and precursors</td> <td class="subtitle2_single centered"> </td> </tr> <tr> <td class="indent1"><strong>Squamous intraepithelial lesions</strong></td> <td class="centered"> </td> </tr> <tr> <td class="indent2">Low-grade squamous intraepithelial lesion</td> <td class="centered">8077/0</td> </tr> <tr> <td class="indent2">High-grade squamous intraepithelial lesion</td> <td class="centered">8077/2</td> </tr> <tr> <td class="indent2">Differentiated-type vulvar intraepithelial neoplasia</td> <td class="centered">8071/2<sup>Δ</sup></td> </tr> <tr> <td class="indent1"><strong>Squamous cell carcinoma</strong></td> <td class="centered">8070/3</td> </tr> <tr> <td class="indent2">Keratinizing</td> <td class="centered">8071/3</td> </tr> <tr> <td class="indent2">Non-keratinizing</td> <td class="centered">8072/3</td> </tr> <tr> <td class="indent2">Basaloid</td> <td class="centered">8083/3</td> </tr> <tr> <td class="indent2">Warty</td> <td class="centered">8051/3</td> </tr> <tr> <td class="indent2">Verrucous</td> <td class="centered">8051/3</td> </tr> <tr> <td class="indent1"><strong>Basal cell carcinoma</strong></td> <td class="centered">8090/3</td> </tr> <tr> <td class="indent1"><strong>Benign squamous lesions</strong></td> <td class="centered"> </td> </tr> <tr> <td class="indent2">Condyloma acuminatum</td> <td class="centered"> </td> </tr> <tr> <td class="indent2">Vestibular papilloma</td> <td class="centered">8052/0</td> </tr> <tr> <td class="indent2">Seborrheic keratosis</td> <td class="centered"> </td> </tr> <tr class="divider_bottom"> <td class="indent2">Keratoacanthoma</td> <td class="centered"> </td> </tr> <tr> <td class="subtitle2_single">Glandular tumors</td> <td class="subtitle2_single centered"> </td> </tr> <tr> <td class="indent1"><strong>Paget disease</strong></td> <td class="centered">8542/3</td> </tr> <tr> <td class="indent1"><strong>Tumors arising from Bartholin and other specialized anogenital glands</strong></td> <td class="centered"> </td> </tr> <tr> <td class="indent2">Bartholin gland carcinomas</td> <td class="centered"> </td> </tr> <tr> <td class="indent2"> <ul class="decimal_heading"> <li>Adenocarcinoma </li> </ul> </td> <td class="centered">8140/3</td> </tr> <tr> <td class="indent2"> <ul class="decimal_heading"> <li>Squamous cell carcinoma </li> </ul> </td> <td class="centered">8070/3</td> </tr> <tr> <td class="indent2"> <ul class="decimal_heading"> <li>Adenosquamous carcinoma </li> </ul> </td> <td class="centered">8560/3</td> </tr> <tr> <td class="indent2"> <ul class="decimal_heading"> <li>Adenoid cystic carcinoma </li> </ul> </td> <td class="centered">8200/3</td> </tr> <tr> <td class="indent2"> <ul class="decimal_heading"> <li>Transitional cell carcinoma </li> </ul> </td> <td class="centered">8120/3</td> </tr> <tr> <td class="indent2">Adenocarcinoma of mammary gland type</td> <td class="centered">8500/3</td> </tr> <tr> <td class="indent2">Adenocarcinoma of Skene gland origin</td> <td class="centered">8140/3</td> </tr> <tr> <td class="indent2">Phyllodes tumor, malignant</td> <td class="centered">9020/3</td> </tr> <tr> <td class="indent1"><strong>Adenocarcinomas of other types</strong></td> <td class="centered"> </td> </tr> <tr> <td class="indent2">Adenocarcinoma of sweat gland type</td> <td class="centered">8140/3</td> </tr> <tr> <td class="indent2">Adenocarcinoma of intestinal type</td> <td class="centered">8140/3</td> </tr> <tr> <td class="indent1"><strong>Benign tumors and cysts</strong></td> <td class="centered"> </td> </tr> <tr> <td class="indent2">Papillary hidradenoma</td> <td class="centered">8405/0</td> </tr> <tr> <td class="indent2">Mixed tumor</td> <td class="centered">8940/0</td> </tr> <tr> <td class="indent2">Fibroadenoma</td> <td class="centered">9010/0</td> </tr> <tr> <td class="indent2">Adenoma</td> <td class="centered">8140/0</td> </tr> <tr> <td class="indent2">Adenomyoma</td> <td class="centered">8932/0</td> </tr> <tr> <td class="indent2">Bartholin gland cyst</td> <td class="centered"> </td> </tr> <tr> <td class="indent2">Nodular Bartholin gland hyperplasia</td> <td class="centered"> </td> </tr> <tr> <td class="indent2">Other vestibular gland cysts</td> <td class="centered"> </td> </tr> <tr class="divider_bottom"> <td class="indent2">Other cysts</td> <td class="centered"> </td> </tr> <tr> <td class="subtitle2_single">Neuroendocrine tumors</td> <td class="subtitle2_single centered"> </td> </tr> <tr> <td class="indent1"><strong>High-grade neuroendocrine carcinoma</strong></td> <td class="centered"> </td> </tr> <tr> <td class="indent2">Small cell neuroendocrine carcinoma</td> <td class="centered">8041/3</td> </tr> <tr> <td class="indent2">Large cell neuroendocrine carcinoma</td> <td class="centered">8013/3</td> </tr> <tr> <td class="indent1"><strong>Merkel cell tumor</strong></td> <td class="centered">8247/3</td> </tr> </tbody> </table> </td> <td class="container"> <table cellspacing="0"> <colgroup width="80%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1_single" colspan="2">Neuroectodermal tumors</td> </tr> <tr class="divider_bottom"> <td class="subtitle2_single">Ewing sarcoma</td> <td class="subtitle2_single centered">9364/3</td> </tr> <tr class="divider_bottom"> <td class="subtitle1_single" colspan="2">Soft tissue tumors</td> </tr> <tr> <td class="subtitle2_single">Benign tumors</td> <td class="subtitle2_single centered"> </td> </tr> <tr> <td class="indent1"><strong>Lipoma</strong></td> <td class="centered">8850/0</td> </tr> <tr> <td class="indent1"><strong>Fibroepithelial stromal polyp</strong></td> <td class="centered"> </td> </tr> <tr> <td class="indent1"><strong>Superficial angiomyxoma</strong></td> <td class="centered">8841/0<sup>Δ</sup></td> </tr> <tr> <td class="indent1"><strong>Superficial myofibroblastoma</strong></td> <td class="centered">8825/0</td> </tr> <tr> <td class="indent1"><strong>Cellular angiofibroma</strong></td> <td class="centered">9160/0</td> </tr> <tr> <td class="indent1"><strong>Angiomyofibroblastoma</strong></td> <td class="centered">8826/0</td> </tr> <tr> <td class="indent1"><strong>Aggressive angiomyxoma</strong></td> <td class="centered">8841/0<sup>Δ</sup></td> </tr> <tr> <td class="indent1"><strong>Leiomyoma</strong></td> <td class="centered">8890/0</td> </tr> <tr> <td class="indent1"><strong>Granular cell tumor</strong></td> <td class="centered">9580/0</td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Other benign tumors</strong></td> <td class="centered"> </td> </tr> <tr> <td class="subtitle2_single">Malignant tumors</td> <td class="subtitle2_single centered"> </td> </tr> <tr> <td class="indent1"><strong>Rhabdomyosarcoma</strong></td> <td class="centered"> </td> </tr> <tr> <td class="indent2">Embryonal</td> <td class="centered">8910/3</td> </tr> <tr> <td class="indent2">Alveolar</td> <td class="centered">8920/3</td> </tr> <tr> <td class="indent1"><strong>Leiomyosarcoma</strong></td> <td class="centered">8890/3</td> </tr> <tr> <td class="indent1"><strong>Epithelioid sarcoma</strong></td> <td class="centered">8804/3</td> </tr> <tr> <td class="indent1"><strong>Alveolar soft part sarcoma</strong></td> <td class="centered">9581/3</td> </tr> <tr> <td class="indent1"><strong>Other sarcomas</strong></td> <td class="centered"> </td> </tr> <tr> <td class="indent2">Liposarcoma</td> <td class="centered">8850/3</td> </tr> <tr> <td class="indent2">Malignant peripheral nerve sheath tumor</td> <td class="centered">9540/3</td> </tr> <tr> <td class="indent2">Kaposi sarcoma</td> <td class="centered">9140/3</td> </tr> <tr> <td class="indent2">Fibrosarcoma</td> <td class="centered">8810/3</td> </tr> <tr class="divider_bottom"> <td class="indent2">Dermatofibrosarcoma protuberans</td> <td class="centered">8832/1<sup>Δ</sup></td> </tr> <tr class="divider_bottom"> <td class="subtitle1_single" colspan="2">Melanocytic tumors</td> </tr> <tr> <td class="subtitle2_single">Melanocytic naevi</td> <td class="subtitle2_single centered"> </td> </tr> <tr> <td class="indent1">Congenital melanocytic naevus</td> <td class="centered">8761/0</td> </tr> <tr> <td class="indent1">Acquired melanocytic naevus</td> <td class="centered">8720/0</td> </tr> <tr> <td class="indent1">Blue naevus</td> <td class="centered">8780/0</td> </tr> <tr> <td class="indent1">Atypical melanocytic naevus of genital type</td> <td class="centered">8720/0</td> </tr> <tr class="divider_bottom"> <td class="indent1">Dysplastic melanocytic naevus</td> <td class="centered">8727/0</td> </tr> <tr class="divider_bottom"> <td class="subtitle2_single">Malignant melanoma</td> <td class="subtitle2_single centered">8720/3</td> </tr> <tr class="divider_bottom"> <td class="subtitle1_single" colspan="2">Germ cell tumors</td> </tr> <tr class="divider_bottom"> <td class="subtitle2_single">Yolk sac tumor</td> <td class="subtitle2_single centered">9071/3</td> </tr> <tr class="divider_bottom"> <td class="subtitle1_single" colspan="2">Lymphoid and myeloid tumors</td> </tr> <tr class="divider_bottom"> <td class="subtitle2_single"><strong>Lymphomas</strong></td> <td class="subtitle2_single centered"> </td> </tr> <tr class="divider_bottom"> <td class="subtitle2_single">Myeloid neoplasms</td> <td class="subtitle2_single centered"> </td> </tr> <tr> <td class="subtitle1_single" colspan="2">Secondary tumors</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class="graphic_footnotes">WHO: World Health Organization; IARC: International Agency for Research on Cancer.<br/>* The morphology codes are from the International Classification of Diseases for Oncology (ICD-O).<sup>[1]</sup> Behavior is coded /0 for benign tumors; /1 for unspecified, borderline, or uncertain behavior; /2 for carcinoma in situ and grade III intraepithelial neoplasia; and /3 for malignant tumors.<br/>¶ The classification is modified from the previous WHO classification of tumors,<sup>[2]</sup> taking into account changes in our understanding of these lesions.<br/>Δ These new codes were approved by the IARC/WHO Committee for ICD-O in 2013.</div><div class="graphic_reference">References:

<ol>
<li>Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology (ICD-O), 3rd ed, World Health Organization, Geneva 2000.</li>
<li>Tavassoli FA, Devilee P. Pathology and Genetics of Tumours of the Breast and Female Genital Organs (IARC WHO Classification of Tumours). International Agency for Research on Cancer, Lyon 2003.</li>
</ol>

Reprinted from: World Health Organization Classification of Tumours of the Female Reproductive Organs, International Agency for Research on Cancer, Vol. 6, Kurman RJ, Carcangiu ML, Herrington S, Young RH, Tumours of the vulva, p. 230, Copyright © 2014.</div><div id="graphicVersion">Graphic 113829 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
